Peptides DB
Research-centric peptide and protocol reference hub

Wolverine Stack (BPC-157/TB-500) record · updated 8h ago

Healing & recoveryInflammation & immuneGrade D · emergingResearch use only
Evidence for its componentsCompare
What is Wolverine Stack (BPC-157/TB-500) used for?

BPC-157 + TB-500 | Tissue Repair & Recovery Protocol

How it works: Body-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling

Primarily researched for · Healing & recoveryRoute · Subcutaneous / oral (research use)

Development stage

where Wolverine Stack (BPC-157/TB-500) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.

Identity
NameWolverine Stack (BPC-157/TB-500)
Full name—
Sequence—
ClassHealing
Research levelWell Studied
Discovered byCurated master list · 2026
Pharmacology
MechanismBody-protective compound (pentadecapeptide); cytoprotective, pro-angiogenic signaling
RouteSubcutaneous / oral (research use)
Half-life—
Time to peak—
Duration—
Extraction confidence0.50
Effect profile · 0–5
Healing & recovery: Healing 5.0, Muscle 2.0, Metabolic 1.0, Neuro 2.0, Sleep 1.0, Immune 4.0, Skin 1.0Healing & recovery — 5.0 / 5Muscle & body comp — 2.0 / 5Metabolic & appetite — 1.0 / 5Neuro & mood — 2.0 / 5Sleep & circadian — 1.0 / 5Inflammation & immune — 4.0 / 5Skin & aesthetics — 1.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin5.02.01.02.01.04.01.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 16, 2026. How this works →
Research stats
Total studies0
Human / animal / cellular0 / 0 / 0
Highest trial phase—
Years covered—
Latest study—
Publication history
No publication years on file
——
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

no studies of its own · newest 12 of 13 from its componentsOpen in the library →
No direct evidence

No study in this library has tested this combination directly. The papers below examined its components individually — each row is labelled with the single compound that study looked at.

Evidence for one component is not evidence for the combination. Nothing below measured what happens when these compounds are used together.

ComponentsBPC-157TB-500
StudyTypeYearSummary depth
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.
FindingNot reported in abstract.
Animal2026Full text read0.70
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
FindingIC50 value of CIARA-1 = 2.52 mM.
In vitro2026Full text read0.70
Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
FindingNot reported in abstract.
mixed2026Full text read0.70
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Finding41.6% to 71.1% of samples failed to meet basic quality criteria.
—2020Full text read0.80
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
FindingIC50 for CIARA-1 = 2.52 mM
In vitro2023Full text read0.80
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery.
FindingNot reported in abstract.
Human2026Full text read0.80
Semantic Scholar search for TB-500 (Thymosin Beta-4)
TakeawayNot reported in abstract.
—2026Title only0.00
Semantic Scholar search for BPC-157
TakeawayNot reported in abstract.
—2010Title only0.00
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
FindingNot reported in abstract.
—2012Partial text0.50
Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.
FindingN-acetylated LKKTETQ detected at 0.02 ng/mL in equine plasma.
Animal2012Full text read0.80
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
FindingNot reported in abstract.
Human2023Partial text0.60
BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185.
TakeawayBPC 157 may have protective effects in healing and neurodegenerative processes, but the evidence is primarily from animal studies and lacks human validation.
Animal2025Title only0.30